Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Swift elimination of undesirable cells is an important feature in tumour suppression and immunity. The tumour suppressor p53 and interferon-alpha and -beta (IFN-alpha/beta) are essential for the induction of apoptosis in cancerous cells and in antiviral immune responses, respectively, but little is known about their interrelationship. Here we show that transcription of the p53 gene is induced by IFN-alpha/beta, accompanied by an increase in p53 protein level. IFN-alpha/beta signalling itself does not activate p53; rather, it contributes to boosting p53 responses to stress signals. We show examples in which p53 gene induction by IFN-alpha/beta contributes to tumour suppression. Furthermore, we show that p53 is activated in virally infected cells to evoke an apoptotic response and that p53 is critical for antiviral defence of the host. Our study reveals a hitherto unrecognized link between p53 and IFN-alpha/beta in tumour suppression and antiviral immunity, which may have therapeutic implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In response to senesce-inducing stimuli, senescent cells produce, in a cGAS-dependent manner, type I interferons that have pro-senescence and anti-proliferative activities.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
In the citing paper
“Indeed, β-interferons increase ROS production, leading to DNA damage and p53 activation [273,274].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“2a ); ISRE is activated by the IFN-activated transcription factor ISGF3, a heterotrimeric complex consisting of a signal transducer and activator of transcription factor 1 (Stat1), Stat2 and interferon regulatory factor 9 (IRF-9”
BackgroundMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“Previous studies have shown that p53 -deficient mice show no sign of abnormality in T and B cells, and that they can mount adaptive immune responses normall”
ResultMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodPapillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024 · cited 1×
“Persistent infection with oncogenic HPV types represents a major risk factor for the development of cervical cancer, in which E6 is known to have a critical role (together with another oncoprotein, E7 (ref”
BackgroundDNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · cited 1×
“We infer that, similar to DNA damage, ATM activation is caused by changes in the chromatin structure in virus-infected cell”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925 · cited 1×
“We also examined the effect of IFN-β on the DNA damage-induced apoptotic response of MEFs expressing the adenovirus E1A oncoprotein, as it is well known that this response is p53-dependent and critical for tumour suppressio”
BackgroundNoxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Self-citation
Research works printed but not linked: 1
- Vilcek, J. & Sen, G. S. in Fields Virology 3rd edn (eds Fields, D. M., Knipe, P. M. & Howley, P. M.) 375–399 (Lippincott-Raven, Philadelphia, 1996)
Cited by
Items 401–500 of 867
ISG15 Deficiency Enhances HIV-1 Infection by Accumulating Misfolded p53
Kuffour, E. O., König, R., Häussinger, D., Schulz, W. A., & Münk, C. (2019) · mBio · doi:10.1128/mbio.01342-19 · Cited by 32
Nonthermal-plasma-mediated animal cell death
Kim, W., Woo, K., Kim, G., & Kim, K. (2010) · Journal of Physics D Applied Physics · doi:10.1088/0022-3727/44/1/013001 · Cited by 34
Mitochondrial RNA , a new trigger of the innate immune system
Grochowska, J., Czerwińska, J., Borowski, L. S., & Szczęsny, R. J. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1690 · Cited by 33
“…replication (Isaacs & Lindenmann, 1957; Schoggins & Rice, 2011), (b) triggering apoptosis in virally infected cells (Stetson & Medzhitov, 2006; Takaoka et al., 2003), (c) stimulating antigen presentation (Ivashkiv & Donlin, 2014), and (d) regulating adaptive immune responses via direct or…”
BackgroundRb/E2F1 Regulates the Innate Immune Receptor Toll-Like Receptor 3 in Epithelial Cells
Taura, M., Suico, M. A., Koyama, K., Komatsu, K., Miyakita, R., Matsumoto, C., Kudo, E., Kariya, R., Goto, H., Kitajima, S., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06454-11 · Cited by 30
Modulation of immune responses by the tumor suppressor p53
Lowe, J. M., Shatz, M., Resnick, M. A., & Menéndez, D. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.2 · Cited by 35
“For example, increased p53dependent apoptosis can reduce viral replication [40].”
BackgroundRoles of p53-Mediated Host–Virus Interaction in Coronavirus Infection
Wang, X., Liu, Y., Li, K., & Hao, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076371 · Cited by 34
“This complex has been shown to activate p53 transcription but is not associated with p53 phosphorylation [46].”
BackgroundUsvasalo, A., Ninomiya, S., Räty, R., Hollmén, J., Saarinen‐Pihkala, U. M., Elonen, E., & Knuutila, S. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20741 · Cited by 29
Hayashi, S., Mizuno, M., Yoshida, J., & Nakao, A. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2008.1 · Cited by 29
Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma
Ternovoi, V. V., Curiel, D. T., Smith, B. F., & Siegal, G. P. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700444 · Cited by 31
Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells
Spaner, D. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0104016 · Cited by 31
Garijo, R., Hernández‐Alonso, P., Rivas, C., Diallo, J., & Sanjuán, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102365 · Cited by 34
Fonseca‐Alves, C. E., Ferreira, E. F., Massoco, C. D. O., Strauss, B. E., Fávaro, W. J., Durán, N., da Cruz, N. O., Cunha, S. C. D. S., Castro, J. L. C., Rangel, M. M. M., et al. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.707025 · Cited by 28
“In addition, transfer of the interferon-β gene not only acts as an immune modulator, but also contributes to the activation of p53 (46).”
BackgroundKasai, K., Ushio, A., Kasai, Y., Sawara, K., Miyamoto, Y., Oikawa, K., Kuroda, H., Takikawa, Y., & Suzuki, K. (2011) · Cancer · doi:10.1002/cncr.26648 · Cited by 28
VZV: immunobiology and host response
Arvin, A. M., & Abendroth, A. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545313.040 · Cited by 29
The promiscuity of ARF interactions with the proteasome
Pollice, A., Vivo, M., & Mantia, G. L. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.09.026 · Cited by 33
Lorenz, L. D., Cardona, J. R., & Lambert, P. F. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003717 · Cited by 28
Guo, H., Fu, X., Li, N., Lin, Q., Liu, L., & Shu-qin, W. (2016) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2016.03.003 · Cited by 28
Rezaei, R., Mahmoudi, M., Gharibdoost, F., Kavosi, H., Dashti, N., Imeni, V., Jamshidi, A., Aslani, S., Mostafaei, S., & Vodjgani, M. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13175 · Cited by 29
STING in cancer immunoediting: Modeling tumor-immune dynamics throughout cancer development
Zhang, X., Chen, Y., Liu, X., Li, G., Zhang, S., Zhang, Q., Cui, Z., Qin, M., Simon, H., Terzić, J., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2024.217410 · Cited by 31
Targeting p53 for immune modulation: Exploring its functions in tumor immunity and inflammation
Wu, H. H., Leng, S., Eisenstat, D. D., Sergi, C. M., & Leng, R. P. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217614 · Cited by 33
Enjoji, M. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i36.5685 · Cited by 27
The master regulators Myc and p53 cellular signaling and functions in polycystic kidney disease
Kurbegovic, A., & Trudel, M. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109594 · Cited by 29
An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1
Qin, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1173467 · Cited by 27
“In the latter, IFN-b signaling was clearly detected using electrophoretic mobility shift assays for active STAT transcriptional complexes including the transcription factor ISGF3 (19).”
BackgroundNeuroprotection Caused by Hyperoxia Preconditioning in Animal Stroke Models
Bigdeli, M. R. (2011) · The Scientific World JOURNAL · doi:10.1100/tsw.2011.23 · Cited by 27
Zhu, Z., Yang, Y., Wei, J., Shao, D., Shi, Z., Li, B., Liu, K., Qiu, Y., Zheng, H., & Ma, Z. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.10.067 · Cited by 27
Gallardo, M., & Calaf, G. M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3477 · Cited by 29
The IRF9-SIRT1-P53 axis is involved in the growth of human acute myeloid leukemia
Tian, W., Guo, R., Wang, F., Jiang, Z., Tang, P., Huang, Y., & Sun, L. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.02.036 · Cited by 27
A Darwinian approach to Huntington’s disease: Subtle health benefits of a neurological disorder
Eskenazi, B. R., Wilson-Rich, N., & Starks, P. T. B. (2007) · Medical Hypotheses · doi:10.1016/j.mehy.2007.02.046 · Cited by 27
Traicoff, J. L., Chung, J., Braunschweig, T. A., Mazo, I. A., Shu, Y., Ramesh, A., D’Amico, M., Galperin, M. M., Knezevic, V., & Hewitt, S. M. (2007) · Journal of Biomedical Science · doi:10.1007/s11373-007-9149-3 · Cited by 27
Interactions ofmiR-34b/candTP53Polymorphisms on the Risk of Intracranial Aneurysm
Li, L., Sima, X., Bai, P., Zhang, L., Sun, H., Liang, W., Liu, J., Zhang, L., & Gao, L. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/567586 · Cited by 26
Yamaji, K., Nabeshima, S., Murata, M., Chong, Y., Furusyo, N., Ikematsu, H., & Hayashi, J. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0005-x · Cited by 28
Tagawa, M., Kawamura, K., Li, Q., Tada, Y., Hiroshima, K., & Shimada, H. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/479013 · Cited by 26
Impact of viruses on airway diseases
Johnston, S. L. (2005) · European Respiratory Review · doi:10.1183/09059180.05.00009503 · Cited by 29
Hao, Z., Fu, F., Cao, L., Guo, L., Liu, J., Xue, M., & Feng, L. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.02.005 · Cited by 26
“It was also reported that p53 can activate ISGs, thereby giving it the ability to amplify the intracellular interferon (IFN) response (Muñoz-Fontela et al., 2011; Takaoka et al., 2003).”
BackgroundInfluentialImmune-related miRNA-mRNA regulation network in the livers of DHAV-3-infected ducklings
Wu, F., Lu, F., Fan, X., Chao, J., Liu, C., Pan, Q., Sun, H., & Zhang, X. (2020) · BMC Genomics · doi:10.1186/s12864-020-6539-7 · Cited by 27
The role of innate immune signals in antitumor immunity
Jinushi, M. (2012) · OncoImmunology · doi:10.4161/onci.1.2.18495 · Cited by 29
Moschos, S. J., & Kirkwood, J. M. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.06.020 · Cited by 31
“In this process, induction of p53 expression by type I interferons plays an important role in the critical decision between cell cycle arrest or apoptosis [32].”
BackgroundYuan, X.-W., Zhu, X., Huang, X.-F., Sheng, P.-Y., He, A.-S., Yang, Z.-B., Deng, R., Feng, G., & Liao, W.-M. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00662.x · Cited by 26
Antiviral Drugs (Other than Antiretrovirals)
Aoki, F. Y., Hayden, F. G., & Dolin, R. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00041-2 · Cited by 28
Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer
Strauss, B. E., Silva, G. R. O., Vieira, I. D. L., Cerqueira, O. L. D., Valle, P. R. D., Medrano, R. F. V., & Mendonça, S. A. (2018) · Clinics · doi:10.6061/clinics/2018/e479s · Cited by 25
PI3K/Akt/p53 pathway inhibits reovirus infection
Zhang, X., Wu, H., Liu, C., Tian, J., & Qu, L. (2015) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2015.06.008 · Cited by 25
“…(IFN-a/b) enhance p53 transcription, and p53 also contributes to the immune responses that lead to the eradication of pathogens, such as viruses (Takaoka et al., 2003). p53 is involved in influenza virus-induced cell death, and inhibiting p53 could increase viral replication (Turpin et al.,…”
Okoshi, R., Ando, K., Suenaga, Y., Sang, M., Kubo, N., Kizaki, H., Nakagawara, A., & Ozaki, T. (2009) · Genes to Cells · doi:10.1111/j.1365-2443.2009.01359.x · Cited by 26
“In addition to the post-translational modifications of p53, several lines of evidence suggest that p53 is transcriptionally activated under certain conditions (Takaoka et al. 2003; Bruno et al. 2006).”
BackgroundSUMOylation of p53 mediates interferon activities
Marcos-Villar, L., Pérez-Girón, J. V., Vilas, J. M., Soto, A., de la Cruz-Herrera, C. F., Lang, V., Collado, M., Vidal, A., Rodríguez, M. S., Muñoz‐Fontela, C., et al. (2013) · Cell Cycle · doi:10.4161/cc.25868 · Cited by 27
Fukubayashi, K., Tanaka, M., Izumi, K., Watanabe, T., Fujie, S., Kawasaki, T., Yoshimaru, Y., Tateyama, M., Setoyama, H., Naoe, H., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.476 · Cited by 25
MicroRNA‐649 promotes HSV‐1 replication by directly targeting MALT1
Zhang, Y., Dai, J., Tang, J., Zhou, L., & Zhou, M. (2016) · Journal of Medical Virology · doi:10.1002/jmv.24728 · Cited by 25
Li, H., Wang, S., Chen, Y., Lǚ, K., Yin, B., Li, S., He, J., & Li, C. (2017) · Scientific Reports · doi:10.1038/srep45821 · Cited by 30
Glaffig, M., Stergiou, N., Schmitt, E., & Kunz, H. (2017) · ChemMedChem · doi:10.1002/cmdc.201700254 · Cited by 25
Dual effects of HTLV-1 bZIP factor in suppression of interferon regulatory factor 1
Mukai, R., & Ohshima, T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.05.014 · Cited by 25
Update on human genetic susceptibility to COVID-19: susceptibility to virus and response
Colona, V. L., Vasiliou, V., Watt, J. L., Novelli, G., & Reichardt, J. K. V. (2021) · Human Genomics · doi:10.1186/s40246-021-00356-x · Cited by 26
Studying Connectivity Properties in Human Protein–Protein Interaction Network in Cancer Pathway
Tomaino, V., Arulselvan, A., Veltri, P., & Pardalos, P. M. (2012) · Springer optimization and its applications · doi:10.1007/978-1-4614-2107-8_10 · Cited by 24
Uka, K., Aikata, H., Mori, N., Takaki, S., Kawakami, Y., Azakami, T., Kawaoka, T., Jeong, S. C., Takahashi, S., & Chayama, K. (2008) · Oncology · doi:10.1159/000151614 · Cited by 24
Oehadian, A., Koide, N., Mu, M., HASSAN, F., ISLAM, S., Yoshida, T., & Yokochi, T. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.11.054 · Cited by 24
Huang, X. F., Nandakumar, V., Tumurkhuu, G., Wang, T., Jiang, X., Hong, B., Jones, L. E., Won, H.-J., Yoshii, H., Ozato, K., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.162 · Cited by 24
Catani, J. P. P., Medrano, R. F. V., Hunger, A., Valle, P. R. D., Adjemian, S., Zanatta, D. B., Kroemer, G., Costanzi-Strauss, E., & Strauss, B. E. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.09.011 · Cited by 30
“Translational Oncology (2016) 9, 565–574”
Kim, J. H., Kim, Y. S., Cho, G. S., Kim, N. H., Gong, C., Lee, B.-J., & Jang, Y. J. (2015) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2015.7.5.489 · Cited by 26
Masuda, K., Teshima-Kondo, S., Mukaijo, M., Yamagishi, N., Nishikawa, Y., Nishida, K., Kawai, T., & Rokutan, K. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050094 · Cited by 27
“]. Similarly, mouse embryonic fibroblasts deficient in the IFNα receptor undergo spontaneous malignant transformation, and the IFNα receptor-deficient mice develop papillomas of the skin at a high rate when treated with a chemical carcinogen [”
Backgroundda Silva, L. F., & Jones, C. (2011) · Journal of Virology · doi:10.1128/jvi.06550-11 · Cited by 25
“Interferon induction has also been linked to apoptosis induction (10, 50), in part by inducing p53 expression (79).”
BackgroundEffect of natural interferon α on proliferation and apoptosis of hepatic stellate cells
Ogawa, T., Kawada, N., & Ikeda, K. (2009) · Hepatology International · doi:10.1007/s12072-009-9129-y · Cited by 26
Chey, S., Claus, C., & Liebert, U. G. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22518 · Cited by 24
“The 2.5- fold increase in the p53 mRNA level in RV-infected MCF-7 is probably due to induction of a type I interferon response, which has been shown to upregulate p53 transcription [Takaoka et al., 2003].”
BackgroundInfluentialp53 Is a Host Cell Regulator during Herpes Simplex Encephalitis
Maruzuru, Y., Koyanagi, N., Takemura, N., Uematsu, S., Matsubara, D., Suzuki, Y., Arii, J., Kato, A., & Kawaguchi, Y. (2016) · Journal of Virology · doi:10.1128/jvi.00846-16 · Cited by 24
Ubiquitination modification: critical regulation of IRF family stability and activity
Liu, B., Jin, J., & Li, Y. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1796-0 · Cited by 23
Anti-interferon alpha autoantibodies and their significance in COVID-19
Petrikov, S. S., Боровкова, Н. В., Попугаев, К. А., Storozheva, M. V., Kvasnikov, A. M., & Godkov, M. A. (2022) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-aaa-1789 · Cited by 23
Structural proteins of Kaposi’s sarcoma-associated herpesvirus antagonize p53-mediated apoptosis
Chudasama, P., Konrad, A., Jochmann, R., Lausen, B., Holz, P., Naschberger, E., Neipel, F., Britzen‐Laurent, N., & Stürzl, M. (2014) · Oncogene · doi:10.1038/onc.2013.595 · Cited by 25
Irie, T., Carnero, E., Okumura, A., García‐Sastre, A., & Harty, R. N. (2007) · Journal of General Virology · doi:10.1099/vir.0.83096-0 · Cited by 23
“For example, Takaoka et al. (2003) reported that cellular p53 was involved in the induction of apoptosis in VSV-infected cells, as well as in pathogenicity in VSV-infected mice.”
BackgroundInfluentialInterferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C
Hino, K., & Okita, K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh031 · Cited by 25
Heinrich, A., Haarmann, H., Zahradnik, S., Frenzel, K., Schreiber, F., Klassert, T. E., Heyl, K. A., Endres, A., Schmidtke, M., Hofmann, J., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201500172r · Cited by 23
Luo, Q., Hu, S., Yan, M., Sun, Z., Chen, W., & Chen, F. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.04.025 · Cited by 28
Qiu, Y., Yang, S., Li, X., Liu, Q., & Ma, Z. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.09.117 · Cited by 23
Chaigne-Delalande, B., Deuve, L., Reuzeau, E., Basoni, C., Lafarge, D., Varon, C., Tatin, F., Anies, G., Garand, R., Kramer, I. M., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050345 · Cited by 25
Akagami, M., Kawada, K., Kubo, H., Kawada, M., Takahashi, M., Kaganoi, J., Kato, S., Itami, A., Shimada, Y., Watanabe, G., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1683-6 · Cited by 23
“1b).(11) In contrast, IFN-c but not IFN-b 3870 M.”
BackgroundInfluentialHastie, E. L., Cataldi, M. P., Steuerwald, N., & Grdzelishvili, V. Z. (2015) · Virology · doi:10.1016/j.virol.2015.04.017 · Cited by 25
“…contrast to previous reports that p53 enhances type I IFN signaling pathway in normal cells and some cancer cell lines (Dharel et al., 2008; Lazo and Santos, 2011; Munoz-Fontela et al., 2005, 2011, 2008; Shin-Ya et al., 2005; Su et al., 2009; Takaoka et al., 2003; Yonish-Rouach et al., 1991).”
BackgroundResultInfluentialShin‐Ya, M., Hirai, H., Satoh, E., Kishida, T., Asada, H., Aoki, F., Tsukamoto, M., Imanishi, J., & Mazda, O. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.088 · Cited by 23
Liu, R., Jacobs, D., Hansen, J., Fu, A., Stevens, R. G., & Zhu, Y. L. (2014) · Cancer Causes & Control · doi:10.1007/s10552-014-0494-z · Cited by 28
TRAIL signaling is proinflammatory and proviral in a murine model of rhinovirus 1B infection
Girkin, J. L. N., Hatchwell, L., Collison, A., Starkey, M. R., Hansbro, P. M., Yagita∥, H., Foster, P. S., & Mattes, J. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00200.2016 · Cited by 22
Role of p53 in pseudorabies virus replication, pathogenicity, and host immune responses
Li, X., Zhang, W., Liu, Y., Xie, J., Hu, C., & Wang, X. (2019) · Veterinary Research · doi:10.1186/s13567-019-0627-1 · Cited by 22
Immune responses to viral infections: Relevance for asthma
Martin, J. G., Siddiqui, S., & Hassan, M. (2006) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2006.04.225 · Cited by 22
RBP‐Jκ binds to and represses transcription of the p53 tumor suppressor gene
Boggs, K., Henderson, B. L., & Reisman, D. (2008) · Cell Biology International · doi:10.1016/j.cellbi.2008.12.005 · Cited by 29
“Takaoka et al. (2003) demonstrated that interferon-a/b, an essential component leading to apoptosis in response to viral infections, activates p53 transcription thus implicating p53 in the interferon pathway.”
BackgroundPreclinical and Clinical Studies
Brewster, M. E., Verreck, G., Bevernage, J., Brouwers, J., den Mooter, G. V., & Augustijns, P. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse529 · Cited by 22
cGAS-STING are responsible for premature aging of telomerase-deficient zebrafish
Şerifoğlu, N., Allavena, G., Lopes-Bastos, B., Marzullo, M., Marques, A., Colibert, P., Bousounis, P., Trompouki, E., & Ferreira, M. G. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00482-5 · Cited by 24
“First, IFN-b signaling was shown to induce p53 transcription (Takaoka et al, 2003).”
Optimal regulation of tumour-associated neutrophils in cancer progression
Reyes, A. A. D. L., V, & Kim, Y. (2022) · Royal Society Open Science · doi:10.1098/rsos.210705 · Cited by 23
RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma
Lambing, S., Tan, Y. P., Vasileiadou, P., Holdenrieder, S., Müller, P., Hagen, C., Garbe, S., Behrendt, R., Schlee, M., van den Boorn, J. G., et al. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad001 · Cited by 23
Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors
Fernández-García, F., Fernández-Rodríguez, A., Torre, C. F., Piñeiro-Yáñez, E., Wang, H., Lechuga, C. G., Callejas, S., Álvarez, R., López-García, A., Esteban-Burgos, L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402913121 · Cited by 23
Wysocka, M., Dawany, N. B., Benoit, B. M., Kossenkov, A. V., Troxel, A. B., Gelfand, J. M., Sell, M. K., Showe, L. C., & Rook, A. H. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.582202 · Cited by 22
Type 1 interferons contribute to the clearance of senescent cell
Katlinskaya, Y. V., Carbone, C. J., Yu, Q., & Fuchs, S. Y. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1056419 · Cited by 25
Hagiwara, S., Kudo, M., Nakatani, T., Sakaguchi, Y., Nagashima, M., Fukuta, N., Kimura, M., Hayakawa, S., & Munakata, H. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604058 · Cited by 21
Self-citationAccumulation of p53 protein in pterygia is not accompanied by TP53 gene mutation
Schneider, B., John‐Aryankalayil, M., Rowsey, J. J., Dushku, N., & Reid, T. W. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2005.05.006 · Cited by 23
IFN-? limitin: a member of type I IFN with mild lympho-myelosuppression
Oritani, K., & Kanakura, Y. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00353.x · Cited by 21
“Induction of tumor suppressor p53 by IFNs is also dependent on the binding of ISGF3 to ISRE in the promoter of the p53 gene [16].”
BackgroundRibavirin enhances interferon signaling via stimulation of mTOR and p53 activities
Su, W.-C., Liu, W., Cheng, C., Chou, Y., Hung, K.-H., Huang, W.-H., Wu, C., Li, Y.-T., Shiau, A., & Lai, M. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.07.027 · Cited by 20
Phan, T. T. T., Truong, N. V., Wu, W., Su, Y.-C., Hsu, T.-S., & Lin, L. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01638-0 · Cited by 21
“Information on primer sequences used in this study is provided in Table S2.”
MethodSmeby, J., Sveen, A., Bergsland, C. H., Eilertsen, I. A., Danielsen, S. A., Eide, P. W., Hektoen, M., Guren, M. G., Nesbakken, A., Bruun, J., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000523 · Cited by 21
Herkt, C. E., Caffrey, B. E., Surmann, K., Blankenburg, S., Salazar, M. G., Jung, A. L., Herbel, S. M., Hoffmann, K., Schulte, L. N., Chen, W., et al. (2020) · mBio · doi:10.1128/mbio.03155-19 · Cited by 20
Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives
Kwok, M., Agathanggelou, A., Davies, N., & Stanković, T. (2021) · Cancers · doi:10.3390/cancers13184681 · Cited by 25
Zhang, F., & Sriram, S. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03104.x · Cited by 24
Ultrasound-mediated interferon β gene transfection inhibits growth of malignant melanoma
Yamaguchi, K., Feril, L. B., Tachibana, K., Takahashi, A., Matsuo, M., Endo, H., Harada, Y., & NAKAYAMA, J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.115 · Cited by 20
Øster, B., Bundgaard, B. B., Hupp, T. R., & Höllsberg, P. (2007) · Journal of General Virology · doi:10.1099/vir.0.83136-0 · Cited by 20
“HHV-6B induces phosphorylation of p53 in its regulatory domain Although p53 may play an important role in antiviral defence (Takaoka et al., 2003), little is known about the crosstalk between HHV-6B and p53.”
BackgroundImpacts of Cross-Linkers on Biological Effects of Mesoporous Silica Nanoparticles
Chen, Y., Wu, S., Chen, I.-C., & Chen, C. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b00240 · Cited by 20
Interferon-driven Metabolic Reprogramming and Tumor Microenvironment Remodeling
Chang, T.-H., & Ho, P. (2025) · Immune Network · doi:10.4110/in.2025.25.e8 · Cited by 22
Harnessing p53 for targeted cancer therapy: new advances and future directions
Andrysík, Z., & Espinosa, J. M. (2025) · Transcription · doi:10.1080/21541264.2025.2452711 · Cited by 22
Effects of Interferons α/β on the Proliferation of Human Micro- and Macrovascular Endothelial Cells
Erdmann, J. I., Vitale, G., van Koetsveld, P. M., Croze, E., Sprij-Mooij, D. M., Hofland, L. J., & van Eijck, C. H. J. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2009.0103 · Cited by 19
“In pathophysiological circumstances, tumor and virus-infected cells have intrinsic and extrinsic co-stimuli; this makes them susceptible to the cytotoxic effects of IFN-b (Tanaka and others 1998; Takaoka and Taniguchi 2003; Takaoka and others 2003).”
Zuo, C., Xia, M., Wu, Q., Zhu, H., LIU, J., & Liu, C. (2014) · Oncology Letters · doi:10.3892/ol.2014.2727 · Cited by 19
Metadata
- Authors
- Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., & Taniguchi, T.
- Affiliations
- The University of Tokyo (JP)
- University of Vienna (AT)
- Sapporo Medical University (JP)
- Corresponding author
- Taniguchi, Tadatsugu
- ORCID
- Venue
- Nature
- Published
- 2003-07
- Volume
- 424
- Issue
- 6948
- Pages
- 516-523
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2119885778
- Cited by
- 847
- References
- 51
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 20 · 2023: 25 · 2022: 22 · 2021: 32 · 2020: 41 · 2019: 40 · 2018: 21 · 2017: 38 · 2016: 50 · 2015: 44 · 2014: 40 · 2013: 46 · 2012: 38
- FWCI
- 20.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Boehringer Ingelheim Japan
- Senri Life Science Foundation
- Kanae Foundation for the Promotion of Medical Science
- Japan Society for the Promotion of Science
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, type I interferon, interferon signaling, tumor suppression, antiviral defense, apoptosis, viral infection, cancer therapy
- MeSH terms
- Animals, Cell Transformation, Neoplastic, DNA-Binding Proteins, Humans, Mice, Inbred C57BL, Neoplasms, RNA, Messenger, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Vesicular stomatitis Indiana virus, Signal Transduction, Transcriptional Activation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Interferon-alpha, Interferon-beta, Apoptosis, Response Elements, Interferon-Stimulated Gene Factor 3, Interferon-Stimulated Gene Factor 3, gamma Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.